首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >NIR-responsive ROS generating core and ROS-triggered 5 '-Deoxy-5-fluorocytidine releasing shell structured water-swelling microgel for locoregional combination cancer therapy
【24h】

NIR-responsive ROS generating core and ROS-triggered 5 '-Deoxy-5-fluorocytidine releasing shell structured water-swelling microgel for locoregional combination cancer therapy

机译:NIR-encooctive ROS生成核心和ROS触发的5'-丁氧基-5-氟核释放壳体结构水膨胀微凝块用于型组合癌症治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Combination chemotherapy now becomes the most standard cancer treatment protocol. Here, we present a core-shell type polymeric microgel (CSPM) which combines photodynamic and chemo therapeutic modalities in one-pot system. CSPM localizes in the malignant lesion after intratumoral injection, releases reactive oxygen species (ROS) and anticancer drug (5'-deoxy-5-fluorocytidine; DFCR) under the near-infrared (NIR) laser treatment. Pheophorbide A (PheoA)-linked poly(hydroxyethyl methacrylate) (poly-HEMA) was designated to a ROS-generating core, and chemically covered with a chitosan shell. In addition, phenylboronic acid was employed in chitosan shells and linked to DFCR to form an ROS cleavable boronic ester. The core-shell structure of CSPM was determined by transmission electron microscopy. NIR-responsive photodynamic ROS generation was confirmed by the oxidative reduction of 9,10-dimethylanthracene (a fluorescent dye), and the cascadic release of DFCR by ROS was confirmed by a release study and a live and dead cell imaging study. Typically, poly-HEMA cored microgel increased its volume by 48.9-fold after absorption of body fluid. This swelling property ensured CSPM was retained in tumor tissues after subtumoral injection and the suitability of CSPM for locoregional photo-therapy. The therapeutic effect of CSPM was attributed to the combined, cascadic deliveries of cytotoxic ROS and DFCR and confirmed by growth inhibition studies in in vitro pancreatic cancer cells and in vivo colon cancer mouse model.
机译:联合化疗现在成为最标准的癌症治疗方案。这里,我们提出了一种核心壳型聚合物微凝胶(CSPM),其将光动力学和化学治疗方式组合在一锅系统中。 CSPM在腹腔内注射后的恶性病变中定位,在近红外(NIR)激光处理下释放反应性氧物种(ROS)和抗癌药物(5'-脱氧-5-荧光细胞; DFCR)。伯苯泡肼A(Pheoa) - 链接聚(羟乙酯)(羟乙酯)(聚-HEMA)被指定为ROS产生核心,并用壳聚糖壳化学覆盖。此外,苯基硼酸在壳聚糖壳中使用,与DFCR连接以形成ROS可切割的硼态酯。 CSPM的核心壳结构由透射电子显微镜测定。通过氧化还原9,10-二甲基蒽(荧光染料)证实了NIR响应的光动力学ROS生成,并且通过释放研究和活细胞成像研究证实了ROS的DFCR的级联释放。通常,在吸收体液后,聚环芯片微凝胶增加了48.9倍的体积。这种膨胀性能确保CSPM在胎体注射后保留在肿瘤组织中,并且CSPM用于招诊所的适用性。 CSPM的治疗效果归因于细胞毒性ROS和DFCR的组合,级联递送,并通过体外胰腺癌细胞的生长抑制研究和体内结肠癌小鼠模型证实。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号